Journal Mobile Options
Table of Contents
Vol. 26, No. 2, 2006
Issue release date: February 2006
Neuroepidemiology 2006;26:83–92

Relationship between Lifetime Smoking, Smoking Status at Older Age and Human Cognitive Function

Stewart M.C.W. · Deary I.J. · Fowkes F.G.R. · Price J.F.
aWolfson Unit for the Prevention of Peripheral Vascular Diseases, Public Health Sciences, University of Edinburgh, and bDepartment of Psychology, University of Edinburgh, Edinburgh, UK

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Cigarette smoking is a major risk factor for clinical cardiovascular disease and may also be associated with poorer cognitive functioning in older age. We measured lifetime cigarette smoking, smoking status and cognitive function in over 2,000 men and women from the general population aged over 50 years with subclinical atherosclerosis (ankle brachial pressure index ≤0.95 but no history of clinical cardiovascular disease). In this population, an association was found between greater lifetime smoking and poorer cognitive function in men and between smoking cessation and better cognitive function in women. The former relationship appeared to reflect an association between smoking habit and prior cognitive function (in early life), whereas the latter remained significant after adjustment for tests of crystallised cognitive function, suggesting a relationship between continuing to smoke (as opposed to quitting) and age-related cognitive decline. Both relationships were inde pendent of the degree of atherosclerosis (as measured using the ankle brachial pressure index), suggesting alternative underlying mechanisms for the association between smoking and human adult cognitive function.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. DeCarli C: Mild cognitive impairment: prevalence, prognosis, aetiology, and treatment. Lancet Neurol 2003;2:15–21.
  2. Graham JE, Rockwood K, Beattie BL, et al: Prevalence and severity of cognitive impairment with and without dementia in an elderly population. Lancet 1997;349:1793–1796.
  3. Deary IJ: Looking Down on Human Intelligence: From Psychometrics to the Brain. Oxford, Oxford University Press, 2000.
  4. Stern PC, Carstensen LL: The Aging Mind: Opportunities in Cognitive Research. Washington, National Academy Press, 2000.
  5. Breteler MMB, Claus JJ, Grobbee DE, Hofman A: Cardiovascular disease and distribution of cognitive function in elderly people: the Rotterdam Study. BMJ 1994;308:1604–1608.
  6. Philips NA, Mate-Kole CC: Cognitive deficits in peripheral vascular disease. A comparison of mild stroke patients and normal control subjects. Stroke 1997;28:777–784.
  7. O’Brien JT, Erkinjuntti T, Reisberg B, Roman G, Sawada T, Pantoni L, Bowler JV, Ballard C, DeCarli C, Gorelick PB, Rockwood K, Burns A, Gauthier S, DeKosky ST: Vascular cognitive impairment. Lancet 2003;2:89–98.
  8. Hofman A, Ott A, Breteler MMB, Bots ML, Slooter AJC, van Harskamp F, et al: Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer’s disease in the Rotterdam study. Lancet 1997;349:151–154.
  9. Prince M, Cullen M, Mann A: Risk factors for Alzheimer’s disease and dementia: a case-control study based on the MRC elderly hypertension trial. Neurology 1994;44:97–104.
  10. Haan MN, Shemanski L, Jagust WJ, Manolio TA, Kuller L: The role of APOE epsilon4 in modulating effects of other risk factors for cognitive decline in elderly persons. JAMA 1999;282:40–46.
  11. Fowkes FGR: The measurement of atherosclerotic peripheral arterial disease in epidemiological surveys. Int J Epidemiol 1988;17:248–254.
  12. Price JF, Mowbray PI, Lee AJ, Rumley A, Lowe GD, Fowkes FGR: Relationship between smoking and cardiovascular risk factors in the development of peripheral arterial disease and coronary artery disease: Edinburgh Artery Study. Eur Heart J 1999;20:344–353.
  13. Howard G, Wagenknecht LE, Burke GL, Diez-Rouz A, Evans GW, McGovern P, et al: Cigarette smoking and progression of atherosclerosis. JAMA 1998;279:119–124.
  14. Emery CF, Huppert FA, Schein RL: Do pulmonary function and smoking behavior predict cognitive function? Finding from a British sample. Psychol Health 1997;12:265–275.

    External Resources

  15. Elwood PC, Gallacher JEJ, Hopkinson CA, Pickering J, Rabbitt P, Stollery B, et al: Smoking, drinking and other life style factors and cognitive function in men in the Caerphilly cohort. J Epidemiol Community Health 1999;53:9–14.
  16. Cerhan JR, Folsom AR, Mortimer JA, Shahar E, Knopman DS, McGovern PG, et al: Correlates of cognitive function in middle-aged adults. Gerontology 1998;44:95–105.
  17. Kalmijn S, van Boxtel MP, Verschuren MW, Jolles J, Launer LJ: Cigarette smoking and alcohol consumption in relation to cognitive performance in middle age. Am J Epidemiol 2002;156:936–944.
  18. Richards M, Jarvis MJ, Thompson N, Wadsworth MEJ: Cigarette smoking and cognitive decline in midlife: evidence from a prospective birth cohort study. Am J Public Health 2003;93:994–998.
  19. Hill RD: Residual effects of cigarette smoking on cognitive performance in normal aging. Psychol Aging 1989;4:251–254.
  20. Launer LJ, Feskens EJM, Kalmijn S, Kromhout D: Smoking, drinking and thinking – the Zutphen study. Am J Epidemiol 1996;143:219–227.
  21. Cervilla JA, Prince M, Mann A: Smoking, drinking and incident cognitive impairment: a cohort community based study included in the Gospel Oak project. J Neurol Neurosurg Psychiatry 2000;68:622–626.
  22. Deary IJ, Pattie A, Taylor MD, Whiteman MC, Starr JM, Whalley LJ: Smoking and cognitive change from age 11 to age 80. J Neurol Neurosurg Psychiatry 2003;74:1006–1007.
  23. Ouriel K, McDonnell AE, Metz CE, Zarins CK: Critical evaluation of stress testing in the diagnosis of peripheral vascular disease. Surgery 1982;91:686–693.
  24. Fowkes FGR, Housley E, Macintyre CCA, Prescott RJ, Ruckley CV: Variability of ankle and brachial systolic pressures in the measurement of atherosclerotic peripheral arterial disease. J Epidemiol Community Health 1988;42:128–133.
  25. Lee AJ, Price JF, Russell MJ, et al: Improved prediction of fatal myocardial infarction using the ankle brachial index in addition to conventional risk factors: the Edinburgh Artery Study. Circulation 2004;110:3075–3080.
  26. Hooi JD, Kester AD, Stoffers HE, et al: Asymptomatic peripheral arterial occlusive disease predicted cardiovascular morbidity and mortality in a 7-year follow-up study. J Clin Epidemiol 2004;57:294–300.
  27. van der Meer I, Bots ML, Hofman A, et al: Predictive value of noninvasive measures of atherosclerosis for incident myocardial infarction: the Rotterdam Study. Circulation 2004;109:1089–1094.
  28. Resnick HE, Lindsay RS, McDermott MM, et al: Relationship of high and low ankle brachial index to all-cause and cardiovascular disease mortality: the Strong Heart Study. Circulation 2004;109:733–739.
  29. Raven J, Raven JC, Court JH: Manual for Raven’s Progressive Matrices and Vocabulary Scales. Oxford, Oxford Psychologists Press, 1998.
  30. Folstein MF, Folstein SE: ‘Mini-mental state’. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189–198.
  31. Lezak MD: Neuropsychological Assessment. New York, Oxford University Press, 1995.
  32. Spreen O, Strauss E: A Compendium of Neuropsychological Tests. Administration, Norms and Commentary. New York, Oxford University Press, 1991.
  33. Wechsler D: Wechsler Adult Intelligence Scale, ed 3. London, Psychological Corporation, 1998.
  34. Zigmond AS, Snaith RP: The hospital anxiety and depression scale. Acta Psychiatr Scand 1983;67:361–370.
  35. McLoone P: Carstairs Scores for Scottish Postcode Sectors from the 1991 Census. Glasgow, Public Health Research Unit, University of Glasgow, 2000, pp 1–119.
  36. Carstairs V, Morris R: Deprivation and mortality: an alternative to social class? Community Med 1989;11:210–219.
  37. Bots ML, Hofman A, Grobbee DE: Common carotid intima-media thickness and lower extremity arterial atherosclerosis: the Rotterdam Study. Arterioscler Thromb 1994;14:1885–1891.
  38. Hedden T, Gabrieli J: Insights into the aging mind: a view from cognitive neuroscience. Neuroscience 2004;2004:87–96.

    External Resources

  39. Deary IJ, Wright AF, Harris SE, et al: Searching for genetic influences on normal cognitive ageing. Trends Cogn Sci 2004;8:178–184.
  40. Deary IJ, Whalley LJ, Crawford JR: An ‘instantaneous’ measure of a lifetime’s cognitive change. Intelligence 2004;32:113–119.

    External Resources

  41. Yarnell JW, Sweetnam PM, Rogers S, Elwood PC, Bainton D, Baker IA, et al: Some long term effects of smoking on the haemostatic system: a report from the Caerphilly and Speedwell Collaborative surveys. J Clin Pathol 1987;40:909–913.
  42. Bots ML, Breteler MM, van Kooten F, Haverkate F, Meijer P, Koudstaal PJ, et al: Coagulation and fibrinolysis markers and risk of dementia. The Dutch vascular factors in dementia study. Haemostasis 1998;28:216–222.
  43. Elwood PC, Pickering J, Gallacher JEJ: Cognitive function and blood rheology: results form the Caerphilly cohort of older men. Age Ageing 2001;30:135–139.
  44. Crawford JR, Deary IJ, Starr JM, et al: The NART as an index of prior intellectual functioning: a retrospective validity study covering a 66-year interval. Psychol Med2001;31:451–458.
  45. Droomers M, Schrijvers CTM, Mackenbach JP: Why do lower educated people continue smoking? Explanations from the longitudinal GLOBE study. Health Psychol 2002;21:263–272.
  46. Taylor MD, Hart CL, Davey Smith G, Starr JM, Hole DJ, Whalley LJ, Wilson V, Deary IJ: Childhood mental ability and smoking cessation in adulthood: prospective observational study linking the Scottish Mental Survey 1932 and the Midspan studies. J Epidemiol Community Health 2003;57:464–465.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50